Impact of CD4+ Lymphocyte Distribution on the Immune Microenvironment, Morphological Changes, and Therapeutic Outcomes in Soft Tissue Sarcomas
Authors
Polatova Jamila Shagayratovna, Karimova Nargiza Mansurovna, Kahharov Alisher Jamoliddinovich

Share
Annotation
This study examines the significance of CD4 lymphocyte localization in the tumor microenvironment of soft tissue sarcomas and their impact on the efficacy of therapy. The analysis showed that intratumoral (intra-umoral) infiltration of these cells is significantly associated with pronounced morphological regression and a high level of therapeutic pathomorphosis, indicating the important role of immune mechanisms in the formation of an antitumor response. Localization of CD4+ T lymphocytes inside the tumor enhances the immune response, stimulates cytotoxic cells and helps to reduce tumor volume, which confirms the theoretical concept of strengthening local immune activation to improve treatment efficacy. At the same time, the effect of CD4 lymphocyte localization on short-term clinical indicators of responses to therapy (complete, partial, stabilization, progression) was statistically insignificant, which indicates the need for further research for a deeper understanding of the mechanisms of interaction between immune cells and the therapeutic effect. The data obtained emphasize the prospects of using CD4 lymphocyte localization as a prognostic marker for assessing the morphological and long-term response, as well as for the development of new methods for optimizing immunotherapy for soft tissue sarcomas.
Keywords
Authors
Polatova Jamila Shagayratovna, Karimova Nargiza Mansurovna, Kahharov Alisher Jamoliddinovich

Share
References:
1. Huang H, Fan Y, Zhang S, Bai X, Wang X, Shan F. Emerging immunotherapy and tumor microenvironment for advanced sarcoma: a comprehensive review. Front Immunol. 2025 May 21;16:1507870. doi: 10.3389/fimmu.2025.1507870. PMID: 40469285; PMCID: PMC12133756
2. van der Graaf WTA, Orbach D, Judson IR, Ferrari A. Soft tissue sarcomas in adolescents and young adults: A comparison with their paediatric and adult counterparts. Lancet Oncol. (2017) 18:e166–e75. doi: 10.1016/s1470-2045(17)30099-2
3. Lee AQ, Hao C, Pan M, Ganjoo KN, Bui N. Use of histologic and immunologic factors in sarcoma to predict response rates to immunotherapy. J Clin Oncol. (2024) 42:11569. doi: 10.1200/JCO.2024.42.16_suppl.11569
4. Wood GE, Meyer C, Petitprez F, D’Angelo SP. Immunotherapy in sarcoma: current data and promising strategies. Am Soc Clin Oncol Educ Book. (2024) 44:e432234. doi: 10.1200/edbk_432234
5. Recine F, Vanni S, Bongiovanni A, Fausti V, Mercatali L, Miserocchi G, et al. Clinical and translational implications of immunotherapy in sarcomas. Front Immunol. (2024) 15:1378398. doi: 10.3389/fimmu.2024.1378398
